See the DrugPatentWatch profile for Trospium
What is Trospium?
Trospium, marketed as Sanctura and Sanctura XR, is an anticholinergic medication used to treat symptoms of overactive bladder (OAB) such as urinary frequency, urgency, and incontinence [1]. It works by blocking the action of acetylcholine on bladder muscles, which helps to relax the bladder and increase its capacity [1].
How does Trospium work?
Trospium is a quaternary ammonium compound that acts as a muscarinic antagonist [1]. It selectively blocks M2 and M3 muscarinic receptors, primarily in the bladder. By inhibiting the binding of acetylcholine to these receptors on the detrusor muscle, trospium reduces involuntary bladder contractions, leading to decreased urinary frequency and urgency, and improved continence [1].
When does Trospium's patent expire?
Information regarding the specific patent expiry dates for Trospium is not readily available in the provided context. DrugPatentWatch.com is a resource that tracks patent information for pharmaceuticals.
Who makes Trospium?
Trospium was originally developed by Astellas Pharma [1].
What are the potential side effects of Trospium?
Common side effects associated with Trospium include dry mouth, constipation, blurred vision, and urinary retention [1]. Less common side effects may include dizziness, drowsiness, and increased heart rate [1].
How does Trospium compare to other OAB medications?
Trospium is one of several medications available for OAB. Other anticholinergic drugs used for OAB include oxybutynin, tolterodine, and solifenacin [2]. These drugs share similar mechanisms of action but can differ in their side effect profiles and efficacy [2]. For instance, some formulations of other anticholinergics may have lower rates of dry mouth compared to immediate-release oxybutynin [2].
What are the risks of taking Trospium?
Patients with certain medical conditions may face increased risks when taking trospium. These include untreated narrow-angle glaucoma, urinary retention, gastric retention, and uncontrolled narrow-angle glaucoma [1]. Due to its anticholinergic effects, caution is advised in elderly patients, especially those with cognitive impairment [1].
Are there generic versions of Trospium available?
Generic versions of trospium chloride are available, which can affect pricing and accessibility [3].
What clinical data supports Trospium's use?
Clinical trials have demonstrated that Trospium effectively reduces the number of OAB episodes and improves bladder capacity [1]. For example, studies have shown significant reductions in daily incontinence episodes and micturitions compared to placebo [1].
Sources:
[1] https://www.drugs.com/trospium.html
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906748/
[3] https://www.goodrx.com/trospium-chloride